Drugmakers will ask US government to pause drug price negotiations, Bloomberg News reports

Published 01/13/2025, 01:30 PM
Updated 01/14/2025, 06:07 AM
© Reuters. FILE PHOTO: The Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake/File Photo
LLY
-

((This Jan. 13 story has been corrected to say 'drugmakers will ask,' not 'Eli Lilly (NYSE:LLY) has asked' to pause negotiations, after the company clarified, in the headline & paragraph 1))

(Reuters) - Drugmakers will ask the U.S. government to pause price negotiations for prescription drugs, Bloomberg News reported on Monday, citing Eli Lilly's CEO David Ricks.

Ricks said at the JPMorgan Healthcare Conference that the government needs to "fix" the Inflation Reduction Act (IRA) before the second round of talks over price cuts, the report added.

The outgoing administration is planning to release a list of the next set of drugs eligible for negotiation before leaving office, Bloomberg reported, citing a person familiar with the matter.

Lilly did not immediately respond to a Reuters request for comment.

© Reuters. FILE PHOTO: The Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake/File Photo

Under the IRA, President Joe Biden's signature legislation, prices for 10 highly popular prescription drugs used by Medicare will be cut by 38% to 79% in 2026.

Regulators are due to announce the list of 15 more drugs by February.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.